CULLINAN THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
CULLINAN THERAPEUTICS, INC. (CGEM) reported Payments to Acquire Debt Securities, Available-for-sale of $34.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $14.57M, a 81.44% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $20.14M, a 84.00% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $19.60M, a 88.34% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $12.57M, a 87.01% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $236.53M, a 67.20% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $721.13M, a 93.13% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $373.38M, a 1.20% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $377.92M, a 28.13% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $34.71M 10-Q · filed 2026-08-06 | $54.30M derived: sum of 3 quarters · filed 2026-08-06 | $66.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.14M 10-Q · filed 2026-05-07 | $39.73M derived: sum of 2 quarters · filed 2026-05-07 | $52.30M derived: sum of 3 quarters · filed 2026-05-07 | $130.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $32.17M derived: sum of 2 quarters · filed 2026-03-10 | $110.69M derived: sum of 3 quarters · filed 2026-08-06 | $236.53M 10-K · filed 2026-03-10 |
| 2025-09-30 | $12.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $91.10M derived: sum of 2 quarters · filed 2026-08-06 | $216.94M 10-Q · filed 2025-11-06 | $384.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $78.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $204.37M 10-Q · filed 2026-08-06 | $372.40M derived: sum of 3 quarters · filed 2026-08-06 | $469.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $125.84M 10-Q · filed 2026-05-07 | $293.88M derived: sum of 2 quarters · filed 2026-05-07 | $390.67M derived: sum of 3 quarters · filed 2026-05-07 | $715.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $168.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $264.83M derived: sum of 2 quarters · filed 2026-03-10 | $589.76M derived: sum of 3 quarters · filed 2026-03-10 | $721.13M 10-K · filed 2026-03-10 |
| 2024-09-30 | $96.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $421.73M derived: sum of 2 quarters · filed 2025-11-06 | $553.10M 10-Q · filed 2025-11-06 | $619.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $324.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $456.30M 10-Q · filed 2025-08-07 | $522.31M derived: sum of 3 quarters · filed 2025-08-07 | $659.09M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $131.37M 10-Q · filed 2025-05-08 | $197.38M derived: sum of 2 quarters · filed 2025-05-08 | $334.16M derived: sum of 3 quarters · filed 2025-05-08 | $415.61M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $66.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $202.79M derived: sum of 2 quarters · filed 2025-02-27 | $284.24M derived: sum of 3 quarters · filed 2025-02-27 | $373.38M 10-K · filed 2025-02-27 |
| 2023-09-30 | $136.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $218.23M derived: sum of 2 quarters · filed 2024-11-07 | $307.37M 10-Q · filed 2024-11-07 | $467.79M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $81.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $170.59M 10-Q · filed 2024-08-08 | $331.01M derived: sum of 3 quarters · filed 2024-08-08 | $455.14M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $89.14M 10-Q · filed 2024-05-15 | $249.56M derived: sum of 2 quarters · filed 2024-05-15 | $373.69M derived: sum of 3 quarters · filed 2024-05-15 | $410.04M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $160.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $284.55M derived: sum of 2 quarters · filed 2024-03-14 | $320.90M derived: sum of 3 quarters · filed 2024-03-14 | $377.92M 10-K · filed 2024-03-14 |
| 2022-09-30 | $124.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $160.48M derived: sum of 2 quarters · filed 2023-11-08 | $217.50M 10-Q · filed 2023-11-08 | $294.76M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $36.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $93.37M 10-Q · filed 2023-08-10 | $170.63M derived: sum of 3 quarters · filed 2023-08-10 | $255.93M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $57.02M 10-Q · filed 2023-05-11 | $134.28M derived: sum of 2 quarters · filed 2023-05-11 | $219.58M derived: sum of 3 quarters · filed 2023-05-11 | $433.07M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $77.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $162.56M derived: sum of 2 quarters · filed 2023-03-09 | $376.05M derived: sum of 3 quarters · filed 2023-03-09 | $525.81M 10-K · filed 2023-03-09 |
| 2021-09-30 | $85.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $298.79M derived: sum of 2 quarters · filed 2022-11-14 | $448.55M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $213.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $363.25M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $149.76M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $69.76M 10-K · filed 2022-03-17 | |||
| 2020-03-31 | $31.09M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |